Trial Profile

A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluciclovine 18F (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms FACBC

Most Recent Events

18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
24 Oct 2016 Results published in The Journal of Urology, according to a Blue Earth Diagnostics media release.
24 Oct 2016 Results published in a Blue Earth Diagnostics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com